Monoclonal antibody capable of being specifically combined with IL-33 as well as preparation method and application of monoclonal antibody
By developing a monoclonal antibody that specifically binds to IL-33, the problem of insufficient binding capacity in existing technologies has been solved, achieving highly efficient blocking of IL-33 and providing a new disease treatment strategy.
CN122060064APending Publication Date: 2026-05-19BIOSION INC
0 Cites 0 Cited by
Patent Information
- Application Number
- CN202411653241.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-11-19
- Publication Date
- 2026-05-19
AI Technical Summary
Technical Problem
The lack of monoclonal antibodies that can specifically bind to IL-33 in the current technology has resulted in poor treatment efficacy for various diseases such as asthma and chronic obstructive pulmonary disease.
Method used
A monoclonal antibody containing a specific amino acid sequence was developed that can bind to IL-33 with high affinity and block its binding to ST2. The preparation method includes the preparation of nucleic acid molecules, expression vector, culture and purification of host cells.
Benefits of technology
It achieves highly effective blocking of IL-33, inhibits the inflammatory response of related diseases, and provides a new strategy for the treatment of asthma, chronic sinusitis, etc.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention belongs to the technical field of biological medicines, and relates to a monoclonal antibody capable of being specifically combined with IL-33 as well as a preparation method and application thereof. The monoclonal antibody capable of being specifically bound with the IL-33 can be specifically bound with the IL-33 in a high-affinity mode, and therefore binding of the IL-33 and a receptor ST2 of the IL-33 is effectively blocked. IL-33 is an important cell factor, and plays a key role in the occurrence and development of various diseases, such as asthma, specific reactive / allergic dermatitis, chronic sinusitis, chronic obstructive pulmonary disease (COPD) and the like. By blocking the combination of IL-33 and ST2, the antibody can inhibit inflammatory reactions mediated by IL-33, and a new strategy is provided for the treatment of these diseases.
Need to check novelty before this filing date? Find Prior Art